Figure 3.

Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Increases Gene Expression through H3K27me3 Demethylation and Histone H3 Acetylation

(A) Transcript levels of indicated genes were measured by qRT-PCR following treatment of ECFCs with vehicle, GSK-343, panobinostat, or GSK-343-panobinostat combination, as indicated. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ±SEM with B2M serving as internal control. (n ≥ 3). ^∗∗∗p < 0.001; ^∗p < 0.05; ns, non-significant.

(B) RNA polymerase II (pol II) binding to indicated gene promoters was assessed by ChIP-qPCR.

(C–E) Enrichment of H3K27me3 (C), H3K4me3 (D), and H3 acetyl (E) histone marks to indicated gene promoters was assessed by ChIP-qPCR.

(B–E) ChIPs were performed using indicated antibodies (Ab) or IgG as a negative control (Mock). qPCR values are expressed as mean fractions of input ±SD.

See also Figure S5.